Tickers

1. Composite Trajectory Verdict

The balance sheet matters most for assessing PURR because its core business is accumulating and holding HYPE tokens, making the fair value of those digital assets the primary driver of financial performance.

Composite Trajectory: Mixed

The balance sheet shows a clear improving trend with HYPE holdings growing from $327.6M to $689.0M to $1.9B across three quarter-ends and equity rising from $589.8M to $743.5M to $1.87B. Earnings are mixed: staking revenue increased from $0.5M in Q2 to $2.6M in Q3 and $9.5M for the full year, but net income swung from a $304.5M loss in Q2 to a $152.5M gain in Q3 and $305.5M for the year, driven almost entirely by volatile unrealized gains/losses on HYPE. Cash flow trajectory cannot be assessed due to lack of comparable standalone quarterly cash flow statements (only cumulative six-month and nine-month periods are provided).

2. Red Flags

• Large one-time loss on HYPE contribution commitment: $169.2M loss recognized at closing due to difference between committed value ($580.5M) and fair value ($411.3M) of 12.5M HYPE tokens (10-K 2026-06-30, MD&A Reverse Recapitalization).
• IPR&D write-off from Sonnet acquisition: $35.6M expense recorded as the acquired in-process R&D had no alternative future use (10-K 2026-06-30, MD&A Results of Operations).
• Deferred tax liability from unrealized gains: $183.5M income tax expense (entirely deferred) created by HYPE appreciation, with no cash tax payment (10-K 2026-06-30, MD&A Results of Operations).
• Operating cash flow negative despite positive net income: FY2026 net income $305.5M vs net cash used in operating activities ($19.1M), reflecting large non-cash adjustments (10-K 2026-06-30, MD&A Cash Flows).
• Heavy reliance on equity financing: $299.9M cash + 12.5M HYPE from Closing PIPE, $646.6M gross proceeds from Equity Facility as of June 30, 2026, and ongoing share issuances to fund HYPE purchases (10-K 2026-06-30, MD&A Equity Facility; 10-K 2026-06-30, MD&A Cash Flows).
• Concentration risk: Treasury assets concentrated in HYPE tokens held with a single custodian; financial results fluctuate materially with HYPE price (10-Q 2026-03-31, Note 1 Risks and Uncertainties).
• Related-party transactions: Advisor (Rorschach Advisors LLC) holds board nomination rights, warrants, and receives equity grants; Guidant equity method investment involves deferred purchase price and service agreement (10-Q 2026-03-31, Note 8).
• Equity Facility derivative expense: Other expense of $11.6M in FY2026 primarily from increase in equity price between trade execution and settlement under the Equity Facility (10-K 2026-06-30, MD&A Other Income (Expense)).
• Simultaneous share repurchases and equity issuances: $10.5M spent on buybacks while issuing shares under Equity Facility and PIPE (10-K 2026-06-30, MD&A Stock Repurchase Program; 10-K 2026-06-30, MD&A Cash Flows).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: Staking revenue grew sequentially from $0.5M in the three months ended Dec 31, 2025 (10-Q 2025-12-31, MD&A Results of Operations Three months ended) to $2.6M in the three months ended Mar 31, 2026 (10-Q 2026-03-31, MD&A Results of Operations Three months ended) and $9.5M for FY2026 (10-K 2026-06-30, MD&A Results of Operations). However, net income is dominated by unrealized fair value changes on HYPE: a $93.2M loss in Q2 (10-Q 2025-12-31, MD&A Results of Operations Three months ended) versus a $198.4M gain in Q3 (10-Q 2026-03-31, MD&A Results of Operations Three months ended) and a $709.9M gain for FY2026 (10-K 2026-06-30, MD&A Results of Operations). The $169.2M loss on HYPE contribution commitment impacted Q2 and FY2026 but not Q3 (10-Q 2025-12-31, MD&A Results of Operations Three months ended; 10-Q 2026-03-31, MD&A Results of Operations Three months ended). SG&A+R&D expenses rose from $3.5M in Q2 to $7.2M in Q3 to $14.0M for the full year (10-Q 2025-12-31, MD&A Results of Operations Three months ended; 10-Q 2026-03-31, MD&A Results of Operations Three months ended; 10-K 2026-06-30, MD&A Results of Operations). Deferred tax expense increased from $17.8M in Q2 to $42.7M in Q3 to $183.5M for FY2026 (10-Q 2025-12-31, MD&A Results of Operations Three months ended; 10-Q 2026-03-31, MD&A Results of Operations Three months ended; 10-K 2026-06-30, MD&A Results of Operations). The swing from a $304.5M net loss in Q2 to a $152.5M net gain in Q3 (10-Q 2025-12-31, MD&A Liquidity; 10-Q 2026-03-31, MD&A Liquidity) illustrates the mixed trajectory: core revenue improving but overall profitability highly volatile.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Insufficient Data

Overall Assessment: The filings provide only cumulative cash flow figures for the six months ended Dec 31, 2025 (10-Q 2025-12-31, MD&A Cash Flows) and nine months ended Mar 31, 2026 (10-Q 2026-03-31, MD&A Cash Flows), plus the full FY2026 (10-K 2026-06-30, MD&A Cash Flows). Standalone quarterly cash flow statements for Q2, Q3, and Q4 are not presented, preventing sequential quarterly trend analysis. FY2026 shows net cash used in operating activities ($19.1M), net cash used in investing ($777.4M, primarily HYPE and USDC purchases), and net cash provided by financing ($934.5M, mainly PIPE proceeds and equity issuances). Without comparable prior-year periods or discrete quarterly cash flows, a trajectory cannot be determined.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Overall Assessment: Across three quarter-ends, HYPE digital assets at fair value increased from $327.6M (Dec 31, 2025) to $689.0M (Mar 31, 2026) to $1.904B (Jun 30, 2026) (10-Q 2025-12-31, MD&A Liquidity; 10-Q 2026-03-31, MD&A Liquidity; 10-K 2026-06-30, MD&A Liquidity). Total assets grew from $616.6M to $810.4M to $2.06B over the same dates (10-Q 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-03-31, Consolidated Balance Sheets; 10-K 2026-06-30, Consolidated Balance Sheets). Stockholders' equity rose from $589.8M to $743.5M to $1.87B (10-Q 2025-12-31, MD&A Liquidity; 10-Q 2026-03-31, MD&A Liquidity; 10-K 2026-06-30, MD&A Liquidity). Cash and equivalents fluctuated: $281.9M (Dec 31) → $113.1M (Mar 31) → $137.9M (Jun 30) (10-Q 2025-12-31, MD&A Liquidity; 10-Q 2026-03-31, MD&A Liquidity; 10-K 2026-06-30, MD&A Liquidity). Deferred tax liabilities grew from $17.8M to $60.5M to $183.5M, tracking HYPE appreciation (10-Q 2025-12-31, MD&A Liquidity; 10-Q 2026-03-31, MD&A Liquidity; 10-K 2026-06-30, MD&A Results of Operations). Working capital (including cash) dipped from $278.0M to $111.0M then recovered to $148.7M (10-Q 2025-12-31, MD&A Liquidity; 10-Q 2026-03-31, MD&A Liquidity; 10-K 2026-06-30, MD&A Liquidity). The consistent accumulation of HYPE tokens and rising equity base reflect an improving balance sheet trajectory aligned with the company's treasury strategy.

6. Data Gaps

• Prior-year comparable periods for any statement (company inception June 13, 2025; no full prior fiscal year or same-quarter priors).
• Standalone Q1 (three months ended Sept 30, 2025) and Q4 (three months ended Jun 30, 2026) income statement and cash flow details.
• Breakdown of staking revenue versus validator commission revenue (validator launched May 13, 2026, after Q3).
• Fair value movements of the Equity Facility derivative asset/liability.
• Contingent Value Rights (CVR) liability valuation and potential dilution.
• Detailed schedule of HYPE token purchases, cost basis, and wallet-level tracking over time.
• Discrete quarterly cash flow statements for Q2, Q3, and Q4 to assess operating, investing, and financing trends.